Engineering CAR T Cells Inside Solid Tumors

Researchers develop targeted lipoplex platform that generates CAR T and NK cells directly within tumors, improving survival in preclinical breast cancer models

October 26, 2026
3 min

The Medicine Maker

At a Glance

Category	Detail
Condition	Solid tumors, studied in mouse models of triple-negative breast cancer
Key Mechanisms	Tumor-targeted R8L-NI@Lipo delivers plasmid DNA encoding an NKG2D-based CAR and IL-15; hypoxia-responsive elements are designed to restrict CAR expression to low-oxygen tumor environments.
Target Population	Preclinical mouse models of 4T1 and EMT6 breast cancer; no human population was studied.
Care Setting	Preclinical research using tumor-targeted genetic delivery and local immune-cell engineering in solid tumors.

Key Highlights

R8L-NI@Lipo incorporates octa-arginine for tumor penetration and O-phospho-L-serine to target GRM4.
The lipoplex accumulated in tumors and penetrated beyond tumor blood vessels; CAR expression was substantially higher under hypoxic conditions.
In 4T1 mice, CD8+ T-cell infiltration was 3.33 times higher than in untreated controls, with increased granzyme B and interferon-gamma expression.
In the 4T1 model, mean tumor weight was approximately 9.2% of control; complete regression occurred in two of six treated mice.
Median survival increased from 22.5 to 42.5 days in 4T1 mice and from 22.5 to 44.5 days in EMT6 mice.

Guideline-Based Recommendations

Diagnosis

Management

The study describes local delivery of plasmid DNA encoding an NKG2D-based CAR and IL-15 using the R8L-NI@Lipo formulation in mouse models.

Monitoring & Follow-up

Experimental assessments included tumor accumulation and penetration, CAR expression under different oxygen conditions, immune-cell infiltration and activation markers, tumor outcomes, survival, and safety.

Risks

Safety experiments suggested that hypoxia-responsive regulation reduced off-target CAR expression and associated inflammatory effects compared with a formulation lacking hypoxia-sensitive regulation.
The findings are preclinical; the article reports no human safety or efficacy results.

Patient & Prescribing Data

No patients were studied; experiments used mouse models of 4T1 and EMT6 breast cancer.

The experimental treatment was a tumor-targeted lipoplex carrying plasmid DNA for an NKG2D-based CAR and IL-15. The article provides no human prescribing or dosing data.

Clinical Best Practices

Interpret the reported antitumor and survival outcomes as preclinical findings from mouse models.
The study selected GRM4 as a delivery target after identifying elevated GRM4 expression in breast cancer tissues.
The formulation used hypoxia-responsive genetic elements intended to restrict CAR expression to low-oxygen tumor environments.